Biopharmaceutical company developing targeted therapies for cancers and bone marrow transplant complications.
Actinium Pharmaceuticals, Inc., a pioneering clinical-stage biopharmaceutical firm, is dedicated to advancing therapies primarily focused on bone marrow transplant (BMT) and adoptive cell therapies. Central to its pipeline is I-131 apamistamab (Iomab-B), currently undergoing pivotal Phase III trials for BMT conditioning in elderly patients with relapsed or refractory acute myeloid leukemia. Additionally, Actinium is engaged in a Phase I study in collaboration with Memorial Sloan Kettering Cancer Center for a CD19-targeted CAR T-cell therapy, showcasing its commitment to cutting-edge cellular therapies.
The company's innovative approach includes leveraging multiple isotopes such as Actinium-225, Iodine-131, and Lutetium-177 across clinical and preclinical development programs. These programs target validated cancer markers like CD45, CD33, CD38, CD47, HER2, and HER3, aiming to enhance the efficacy of therapies for bone marrow transplant and cancer treatments either as standalone therapies or in combination with other modalities.
Actinium Pharmaceuticals collaborates with industry leaders like Astellas Pharma, Inc. to develop theranostics for solid tumor indications and EpicentRx, Inc. on novel CD47 immunotherapy targeted radiotherapy. Additionally, its partnership with AVEO Oncology focuses on developing ARC therapies targeting HER3 for solid tumors, further broadening its therapeutic scope and potential impact.
Founded in 2000 and headquartered in New York, New York, Actinium Pharmaceuticals continues to drive innovation in biopharmaceuticals, striving to address critical medical needs through its advanced research and strategic collaborations in oncology and cellular therapy.